Sergio Dompé
Angel Investor
Sergio Dompé is a venture - series unknown investor focused on Fitness and Robotics. Born in Milan October 14, 1955, Sergio Dompé Group's President eponymous biopharmaceuticals, focused on the development of innovative therapeutic solutions for rare diseases, often orphan care.Entrepreneur of the Pharmaceutical and Biotechnology industry, have been conferred, in 1996, an Honorary Degree in Biotechnology with pharmaceuticaladdress (Bologna), in 2005 in Medical Biotechnology (L'Aquila) and 2010 in Pharmacy (Urbino).Among the first in Italy to realize the true value of biotechnology applied to human health, it developed a dense network of partnerships with the most important research centers in diseases in the therapeutic areas in which concentrates its efforts Dompé.To date, Dompé has consolidated its commitment to R & D by promoting 21 clinical trials involving 1,200 patients worldwide, conducted in collaboration with an international network of 200 research centers.In 2016 finances and gives life to Movendo Company, an innovative medical company founded by the Italian Institute of Technology to develop the most advanced technologies in the service and products in the field of rehabilitation.In 2016 Sergio Dompé has been awarded the Foundation Aid to Research in Rare Diseases Award (ARMR), an award given to people who have distinguished themselves for their commitment in research, understood as a living witness.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Sergio Dompé invests in
Stages Sergio Dompé invests in
Countries Sergio Dompé invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Fitness 1 (100%)
- Robotics 1 (100%)
- Wellness 1 (100%)
- Health Care 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Movendo Technology is a medical company that designs and produces innovative robotic technologies for rehabilitation using the know-how within the Italian Institute of Technology (www.iit.it), a research center leader in robotics, neuroscience, nanotechnology, renewable energies, graphene, and computation.Movendo Technology has been funded bySergio Dompè president of Sergio Dompè Farmaceutici, a Bio-Pharmaceutical company. | $11M / Venture - Series Unknown / Jan 02, 2017 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Sergio Dompé invest in?
Sergio Dompé invests primarily in Fitness, Robotics and Wellness startups, most often at Venture - Series Unknown stage. Most of the 1 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sergio Dompé?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sergio Dompé last invest?
The most recent investment recorded for Sergio Dompé closed in Jan 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!